Duong Son Q, Zhang Yulin, Hall Matt, Hollander Seth A, Thurm Cary W, Bernstein Daniel, Feingold Brian, Godown Justin, Almond Christopher
Pediatrics (Cardiology), Stanford University School of Medicine, Palo Alto, California, USA.
Children's Hospital Association, Lenexa, Kansas, USA.
Pediatr Transplant. 2021 Sep;25(6):e14035. doi: 10.1111/petr.14035. Epub 2021 May 18.
Routine surveillance biopsy (RSB) is performed to detect asymptomatic acute rejection (AR) after heart transplantation (HT). Variation in pediatric RSB across institutions is high. We examined center-based variation in RSB and its relationship to graft loss, AR, coronary artery vasculopathy (CAV), and cost of care during the first year post-HT.
We linked the Pediatric Health Information System (PHIS) and Scientific Registry of Transplant Recipients (SRTR, 2002-2016), including all primary-HT aged 0-21 years. We characterized centers by RSB frequency (defined as median biopsies performed among recipients aged ≥12 months without rejection in the first year). We adjusted for potential confounders and center effects with mixed-effects regression analysis.
We analyzed 2867 patients at 29 centers. After adjusting for patient and center differences, increasing RSB frequency was associated with diagnosed AR (OR 1.15 p = 0.004), a trend toward treated AR (OR 1.09 p = 0.083), and higher hospital-based cost (US$390 315 vs. $313 248, p < 0.001) but no difference in graft survival (HR 1.00, p = 0.970) or CAV (SHR 1.04, p = 0.757) over median follow-up 3.9 years. Center RSB-frequency threshold of ≥2/year was associated with increased unadjusted rates of treated AR, but no association was found at thresholds greater than this.
Center RSB frequency is positively associated with increased diagnosis of AR at 1 year post-HT. Graft survival and CAV appear similar at medium-term follow-up. We speculate that higher frequency RSB centers may have increased detection of clinically less important AR, though further study of the relationship between center RSB frequency and differences in treated AR is necessary.
进行常规监测活检(RSB)以检测心脏移植(HT)后无症状急性排斥反应(AR)。各机构间儿科RSB的差异很大。我们研究了RSB基于中心的差异及其与移植失败、AR、冠状动脉血管病变(CAV)以及HT后第一年护理费用的关系。
我们将儿科健康信息系统(PHIS)与移植受者科学注册系统(SRTR,2002 - 2016年)相链接,纳入所有0至21岁的初次HT患者。我们根据RSB频率(定义为年龄≥12个月且第一年无排斥反应的受者中活检次数的中位数)对中心进行特征描述。我们使用混合效应回归分析对潜在混杂因素和中心效应进行校正。
我们分析了29个中心的2867例患者。在调整患者和中心差异后,RSB频率增加与确诊AR相关(OR 1.15,p = 0.004),有治疗AR的趋势(OR 1.09,p = 0.083),以及更高的医院费用(390315美元对313248美元,p < 0.001),但在中位随访3.9年期间移植存活率(HR 1.00,p = 0.970)或CAV(SHR 1.04,p = 0.757)无差异。中心RSB频率阈值≥2次/年与未校正的治疗AR发生率增加相关,但高于此阈值未发现关联。
中心RSB频率与HT后1年AR诊断增加呈正相关。中期随访时移植存活率和CAV似乎相似。我们推测RSB频率较高的中心可能增加了对临床重要性较低的AR的检测,不过有必要进一步研究中心RSB频率与治疗AR差异之间的关系。